14P Preclinical evaluation of intermittent dosing regimens on antitumor and PD activity of SY-5609, a potent and selective oral CDK7 inhibitor, in ovarian cancer xenografts
L. Johannessen,W. Dworakowski,P. Sawant,N. Ke,A. Lefkovith,A. D'Ippolito,M. Eaton,S. H. Henry,G. Hodgson
